Developer Applies for Use of CAR T-Cell Therapy in DLBCL
November 6th 2017Novartis has submitted an application to the FDA to extend the indications for its CAR T-cell therapy tisagenlecleucel (Kymriah) for its use in adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant.
Personalized Medicine Moving to Forefront of Hematologic Malignancies
November 3rd 2017Edward A. Stadtmauer, MD, sheds light on the future of chimeric antigen receptor T-cell therapy, systemic therapeutic advances in the field of acute myeloid leukemia, and remaining challenges in the multiple myeloma paradigm.
Study: CAR T-Cell Therapy Highly Effective in High-Risk Chronic Lymphocytic Leukemia
October 20th 2017CD19 CAR T cells are highly effective in high-risk patients with chronic lymphocytic leukemia who have failed to respond to treatment with ibrutinib, a Bruton's tyrosine kinase inhibitor, according to a new study.
In Conversation With a Pharmacist: Management of CAR T-Cell Treatment
October 13th 2017Evidence-Based OncologyTM sat down with Brandon R. Shank, PharmD, MPH, BCOP, clinical pharmacy specialist, Division of Pharmacy, The University of Texas MD Anderson Cancer Center, to understand a pharmacist's role in administering chimeric antigen receptor (CAR) T cells.
Dacomitinib Tops Gefitinib in First-Line EGFR-Mutant NSCLC
October 10th 2017The second-generation EGFR tyrosine kinase inhibitor dacomitinib significantly improved progression-free survival over gefitinib as a first-line therapy for EGFR–positive non–small-cell lung cancer, according to a randomized phase III trial.
Debating the True Benefit of Adjuvant TKIs in High-Risk RCC
October 4th 2017Adjuvant therapy with tyrosine kinase inhibitors for patients with high-risk renal cell carcinoma (RCC) who have undergone a nephrectomy may be supported by level IIa evidence from the National Comprehensive Cancer Network guidelines.
Rituximab Maintenance Therapy Can Improve Outcomes in Mantle Cell Lymphoma
September 28th 2017Maintenance therapy with rituximab following autologous stem cell transplantation prolonged progression-free, event-free, and overall survival compared with observation in patients with mantle cell lymphoma, according to a new study.
JAMA Commentary Urges Realistic View of New CAR T-Cell Cancer Therapy
September 25th 2017While the FDA’s approval of the immunotherapy tisagenlecleucel represents a landmark in the oncology field, the treatment is far from being a cure and should be viewed in context of its $475,000 price tag, a group of oncologists wrote in a commentary published in JAMA.
Immune Adverse Events From Nivolumab Predict Better Survival With NSCLC
September 23rd 2017When immune-related adverse events arise from nivolumab, it may indicate that the therapy is having greater efficacy against non—small-cell lung cancer (NSCLC), as a new study demonstrates a link between these events and improved survival outcomes.